{
  "@context": {
    "bioagents": "https://bio.agents/ontology/",
    "bsc": "http://bioschemas.org/",
    "bsct": "http://bioschemas.org/types/",
    "dct": "http://purl.org/dc/terms/",
    "edam": "http://edamontology.org/",
    "owl": "http://www.w3.org/2002/07/owl#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://bio.agents/vepad",
      "@type": "sc:SoftwareApplication",
      "dct:conformsTo": "https://bioschemas.org/profiles/ComputationalAgent/0.6-DRAFT",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_3517"
        },
        {
          "@id": "edam:topic_0199"
        },
        {
          "@id": "edam:topic_3474"
        },
        {
          "@id": "edam:topic_3360"
        },
        {
          "@id": "edam:topic_0634"
        }
      ],
      "sc:citation": [
        "pubmed:32828070",
        {
          "@id": "https://doi.org/10.1016/J.COMPBIOMED.2020.103933"
        }
      ],
      "sc:description": "Predicting the effect of variants associated with Alzheimer's disease using machine learning.\n\nVEPAD is a agent for scoring the effect of Single Nucleotide Variants with respect to Alzheimer's Disease in the human genome. VEPAD makes use of 7 histone marks from multiple brain tissues, combined with 2 conservation scores, GC content and CpG site features at and around the point of mutation to assign scores to the variants.",
      "sc:featureList": [
        {
          "@id": "edam:operation_0331"
        },
        {
          "@id": "edam:operation_3225"
        }
      ],
      "sc:name": "VEPAD",
      "sc:url": "http://web.iitm.ac.in/bioinfo2/vepad/"
    },
    {
      "@id": "https://doi.org/10.1016/J.COMPBIOMED.2020.103933",
      "@type": "sc:CreativeWork"
    }
  ]
}